As of 14 Oct 2026, Addition Therapeutics has raised $100M across 1 verified round on record; latest: $100 million Series A, announced 17 Dec 2025.
Additiontx sells genetic medicines using their PRINT technology to address severe lifelong diseases in patients.
1 source
The article says a half dozen investors backed the Series A but names only SR One, Pivotal Life Sciences and Abingworth.
Published by hand (biopharmadive.com): "Addition Therapeutics has emerged from stealth with $100 million in hand to develop new types of gene therapies that might work against rare as well as chronic diseases.": Checked by hand: BioPharma Dive states the $100M.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-12-17 | not stated | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source The article says a half dozen investors backed the Series A but names only SR One, Pivotal Life Sciences and Abingworth. Published by hand (biopharmadive.com): "Addition Therapeutics has emerged from stealth with $100 million in hand to develop new types of gene therapies that might work against rare as well as chronic diseases.": Checked by hand: BioPharma Dive states the $100M. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: biopharmadive.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||